Views

Rare Diseases Challenge Modelers to Deliver Equity
In the rare disease space modelers must embrace a wide variety of new challenges and be part of a wider multidisciplinary team in order to bring new treatments to address these often devastating rare diseases.
View Feb 27, 2025
Fundraising in Oncology Biotech: A Cynical Reflection for Optimistic Action
An article from January 2nd on Endpoints News titled, “A look at biotech's year of the megaround” reports that the biotech industry saw 96 nine-figure funding rounds in 2024. About one-third were preclinical and nearly the same amount for Phase 1. Most were Series A or B, with roughly one-third being oncology, in part or in entirety.
View Jan 23, 2025